A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Presence of a complex karyotype did not affect progression-free or overall survival.
Results of a subgroup analysis suggest promising clinical activity.
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Researchers found leukemias trending higher as the ‘baby boomer’ generation ages. Interestingly, incidence of all cancers was not correlated with the increase in older Americans.
Further studies needed to look at relevance outside of the transplant-eligible population.
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
The combination of the antiproliferative agent ibrutinib, with the proapoptotic agent venetoclax, may target the dual pathophysiology characteristic of CLL.
A retrospective study sought to determine the risk of solid-tumor second malignancy associated with an infectious etiology for patients with certain lymphomas or leukemias.
Mutated ATM and unmutated IGHV were identified as potential early drivers of disease in treatment-naive patients with chronic lymphocytic leukemia.
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy.
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
Results of this study suggest that the clonal and subclonal characteristics of early-stage CLL shape the dynamics of the disease course.
Patients with CLL who had symptomatic bronchial involvement had a significantly higher proportion of anomalies in small airways and peripheral bronchi.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Interestingly, over two-thirds of patients did not receive active treatment for CLL during the study period.
Patients with chronic lymphocytic leukemia who received venetoclax plus obinutuzumab had better survival outcomes compared with chemoimmunotherapy.
Chimeric antigen receptor T-cell therapy “liso-cel” was deemed safe and clinically active in chronic lymphocytic leukemia and small lymphocytic leukemia.
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.